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IL-12 stimuli during ex vivo expansion not only
prevents the upregulation of PD1 on tumor
infiltrating adoptively transferred T cells but also
on endogenous TILs which results in effective
tumor regression
C Marcela Diaz-Montero1*, Yu Yang1, Patricia A Rayman1, Alberto Montero1, Charlie Tannenbaum1, James Finke2
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
The blockade of negative immune regulators such as
CTLA-4 and PD1 continues to show encouraging results
in patients with solid malignancies. The efficacy of these
therapies could be further enhanced in a combinatorial
setting that includes adoptive cell therapy (ACT), and
thus it is important to clearly understand the relative
impact that checkpoint blockade has on the anti-tumor
activity of transferred and endogenous CD8+ T cell
populations. Low ACT efficacy is associated with
increased levels of PD1 by tumor infiltrating transferred
T cells; IL-12 stimulation during activation prevents the
re-expression of PD1 within the tumor. Here we show
that ex vivo activation of Pmel cells in the presence of
IL-12 (Pmel12) not only maintains low levels of PD1
expression once they reach the tumor, but also has an
impact on the expression of PD1 by endogenous tumor
infiltrating lymphocytes (TILs). Low levels of PD1
expression by both tumor infiltrating Pmel12 cells and
TILs correlated with effective regression of primary
tumors. In the periphery, however, both endogenous
and transferred CD8+ T cells showed low levels of PD1
expression regardless of IL-12 stimuli during ex vivo
activation. We assessed the ability of these circulating
CD8+ T cell populations to prevent the dissemination of
tumors following intravenous injection of B16 mela-
noma cells. Mice treated with either Pmel12 cells or
Pmel cells activated in the presence of antigen only
(PmelAg) were both able to effectively prevent the spread
of tumor cells to the lung. Interestingly, this occurred
despite robust progression of primary tumors in mice
treated with PmelAg cells. This differential expression of
PD1 between tumor infiltrating (high PD1) and circulat-
ing tumor reactive CD8+ T cells (low PD1) might
explain the failure to control the progression of localized
tumor lesions after transfer of PmelAg cells while effec-
tively preventing the establishment of distant ones.
These findings suggest that factors within the tumor
other than antigen modulate the expression of PD1 on
infiltrating T cells. Thus, expanding T cells for ACT in
the presence of IL-12 represents a feasible strategy to
protect tumor infiltrating CD8+ T cells from tumor
derived PD1-inducing factors which otherwise would
hinder the efficacy of ACT.
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